ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

follitropin alfa

Also written as “Gonal-f”, “Follitropin alfa (Primapur)” and “Gonal-f®”.

Its studies are mostly in Infertility · Infertility, Female · Hypogonadism · Anovulation, led by 10 companies.

Drug pageFollitropin alfa: every studyMany companies study it; this page follows only the 23 they lead. All 49 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 4, 200523 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germanyits history only131 open or runningphase 4since Nov 4, 2005Nov 4, 2005Sep 30, 2027phase 3 · NCT07340827
IVFarmaits history only20 open or runningphase 3since Mar 2, 2017Mar 2, 2017none ahead
Bharat Serums and Vaccinesits history only11 open or runningphase 3since Jan 23, 2022Jan 23, 2022none ahead
Changchun GeneScience Pharmaceuticalits history only10 open or runningphase 3since Jan 5, 2015Jan 5, 2015none ahead
Fertility Biotechits history only10 open or runningphase 1since May 19, 2015May 19, 2015none ahead
Finoxits history only10 open or runningphase 3since May 10, 2010May 10, 2010none ahead
Gema Biotechits history only10 open or runningphase 3since May 22, 2015May 22, 2015none ahead
IBSA Institut Biochimique10 open or runningphase 3since Sep 15, 2006Sep 15, 2006none ahead
MinaPharm Pharmaceuticalsits history only10 open or runningphase 4since Nov 30, 2016Nov 30, 2016none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 1since Mar 4, 2025Mar 4, 2025none ahead

Also a collaborator on its studies: Merck Serono Middle East FZ, Merck Serono GmbH, Germany, Merck Serono Co., Ltd., Japan and Merck Serono S.P.A., Italy.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of IBSA Institut Biochimique only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2006First study: phase 3 study in InfertilityFirst studyNCT00378001 · 152 enrolled · United States

TargetBeta

FSHR →read by rule
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule

Other programs on FSHR

ProgramCompanyFurthest phaseStudies
Follicle Stimulating Hormoneruleglycotope-gmbhphase 46
follitropin deltaruleFerring Pharmaceuticalsphase 318

Studies

The one study IBSA Institut Biochimique leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00378001Infertility · United States3CompletedMay 2006152

How it is read

Names in the registry

  • “Gonal-f”, 2 entries
  • “Follitropin alfa (Primapur)”, 2 entries
  • “Gonal-f®”, 2 entries
  • “GONAL-f®”, 2 entries
  • “GONAL f® prefilled pen”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.